Ranbaxy ties up with UK firm to market its cancer pill

By SiliconIndia   |   Tuesday, 29 October 2002, 08:00 Hrs
Printer Print Email Email
Ranbaxy Laboratories, a pharmaceutical company, on Monday signed an agreement with UK-based K S Biomedix for marketing TransMID, a new biological drug for treatment of high grade glicoma, a terminal brain cancer.



NEW DELHI: Brian Tempest, Ranbaxy pharmaceutical president, said, "We will continue to provide novel products for Indian customers and believe that TransMID will help us strengthen our position in the high value oncology segment,"

Dr Steven Powell, CEO of K S Biomedix, said, "This latest agreement is the fourth territory licensed for TransMID this year, extending the commercial coverage for the product significantly."


SPOTLIGHT
GST rate cut to spur Bengaluru
The realty market in India's tech hub is set to grow as lower Goods and Services Tax (GST) rate..
Ola raises Rs 400 cr for electric
Leading ride-hailing cab aggregator Ola on Friday said it raised Rs 400 crore from its early in..
SpiceJet plans aggressive
Budget passenger carrier SpiceJet plans to aggressively expand its international networks to fl..
Fossil Group sells smartwatch
Global watch and accessories maker Fossil Group has announced to sell its smartphone technolog..